Eton Pharmaceuticals

What Eton Pharmaceuticals does

Eton Pharmaceuticals is a commercial-stage rare disease pharmaceutical company founded in 2017 and listed on NASDAQ (ETON), headquartered in Deer Park, Illinois. The company acquires, develops, and commercializes treatments for rare diseases — predominantly ultra-rare pediatric endocrine and metabolic disorders — by sourcing approved or near-approved molecules globally (US and Europe), pursuing FDA approval through known regulatory pathways, and commercializing through specialty pharmacy networks. Its core technology centers on proprietary formulations of approved molecules designed to be safer, more effective, or more convenient than existing products, including the first and only FDA-approved oral liquid desmopressin (DESMODA, patent protection through 2044) and pediatric-appropriate hydrocortisone formulations (ALKINDI SPRINKLE, KHINDIVI).

The company's commercial portfolio comprises approximately ten products spanning pediatric endocrinology (Increlex for severe IGF-1 deficiency, ALKINDI SPRINKLE, KHINDIVI), inherited metabolic disorders (Carglumic Acid, Betaine Anhydrous, Nitisinone, PKU GoLike, TYR GoLike), Wilson disease (GALZIN), infantile hemangioma (HEMANGEOL), central diabetes insipidus (DESMODA), and leishmaniasis (IMPAVIDO, rights effective September 2026). Two pipeline candidates — ET-700 (extended-release zinc acetate for Wilson disease, in clinical study) and ET-801 (ready-to-use hydrocortisone for adrenal insufficiency crises, partnered with CROSSJECT) — represent the next growth layer. Products are distributed primarily through Anovo Specialty Pharmacy under an exclusive relationship, supported by the Eton Cares patient support program offering $0 co-pay for eligible commercially insured patients.

Eton's business model is asset-light and deal-driven: revenue is generated through product sales and licensing royalties, with growth funded by a cadence of in-licensing and acquisition transactions (Increlex from Ipsen in late 2024, HEMANGEOL from Pierre Fabre effective May 2026, IMPAVIDO from Knight Therapeutics effective September 2026). The model emphasizes rapid commercialization of products with existing safety/efficacy data and demonstrated demand (including off-label or compounding patterns), reducing development risk and time-to-market. Q1 2026 product sales reached $24.3M (+73% YoY) with management guiding full-year 2026 revenue to >$120M (raised from $110M) and targeting $200M by 2027 and $500M by 2030. The company reported positive net income and adjusted EBITDA in Q1 2026, marking a profitability inflection.

Name

Eton Pharmaceuticals

Legal name

Eton Pharmaceuticals, Inc.

Website

https://etonpharma.com

Company type

Public

Founded year

2017

Operating status

Operating

Headcount range

51–100 employees

Short description

Eton Pharmaceuticals is a commercial-stage rare disease pharmaceutical company that acquires, develops, and commercializes proprietary formulations of approved molecules for ultra-rare pediatric endocrine, metabolic, and specialty conditions, distributing ten products primarily through specialty pharmacy partners in the US.

Ownership category

akta.pro rank

Product category

Rare Disease Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)

akta.pro secondary industries

Rare Pediatric & Congenital Disorder Therapies (HLAIAIAN), Specialty Care Pharmaceuticals (HLAIAAAB), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Rare disease pharmaceuticals
• Specialty pharmaceutical products
• Pediatric endocrinology treatments
• Proprietary drug formulations
• Metabolic disorder therapies

Headquarters

HQ city

Studio City

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Operations

Revenue model

1. Product Sales: Revenue generated from the sale of commercial rare disease products including INCRELEX, ALKINDI SPRINKLE, GALZIN, Carglumic Acid, KHINDIVI, HEMANGEOL, DESMODA, Betaine, Nitisinone, and PKU GoLike. Products are distributed through specialty pharmacy partners.
2. Royalty Revenue: Eton receives royalty payments from licensed products in their portfolio.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Eton Pharmaceuticals acquires, develops, and commercializes FDA-approved rare disease treatments, including proprietary formulations of approved molecules for pediatric endocrinology, metabolic disorders, and other rare conditions. The company focuses on products with existing safety and efficacy data, targeting rapid commercialization through specialty pharmacy networks. Its commercial portfolio spans ten-plus products including Alkindi Sprinkle, DESMODA, Galzin, Hemangeol, Increlex, Khindivi, Betaine Anhydrous, Carglumic Acid, Nitisinone, PKU GoLike, TYR GoLike, and IMPAVIDO.

Product overview

Eton Pharmaceuticals is a rare disease-focused pharmaceutical company that develops and commercializes treatments for underserved patient populations. The company's product portfolio consists of eleven commercial rare disease products spanning pediatric endocrinology (Alkindi Sprinkle, Khindivi, Increlex), metabolic disorders (Carglumic Acid, Betaine Anhydrous, Nitisinone), rare genetic conditions (Galzin for Wilson disease, PKU GoLike, TYR GoLike), and specialized therapeutics (Hemangeol for infantile hemangioma, Desmoda for diabetes insipidus, IMPAVIDO for leishmaniasis). Eton also maintains a pipeline of development candidates including ET-700 for Wilson disease and ET-801 for adrenal insufficiency. The company operates through a business model focused on acquiring, licensing, and rapidly commercializing approved therapies with existing safety and efficacy data, distributing products primarily through specialty pharmacy partners like Anovo.

Differentiator

Problem solved

Functional benefit

Brands

• Eton Cares: Patient support program offering $0 co-pay for eligible commercially insured patients and expanded assistance programs
• Alkindi Sprinkle
• Desmoda
• Hemangeol
• Increlex
• Galzin
• Khindivi
• PKU GoLike
• Carglumic Acid
• Betaine Anhydrous
• Nitisinone

Products and services

• Alkindi Sprinkle

Quantifiable outcome

• DESMODA projected peak annual sales of $30-50 million
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Knight TherapeuticscoreChannel Partner/ Reseller/ Distributor · 19 May 2026Eton acquired exclusive U.S. commercialization rights to IMPAVIDO (miltefosine), the first and only FDA-approved oral therapy for visceral, cutaneous, and mucosal leishmaniasis, from Knight Therapeutics. Rights take effect September 26, 2026. This expands Eton's rare disease portfolio and adds another 2026 product launch.
• Anovo Specialty PharmacycoreChannel Partner/ Reseller/ Distributor · 1 May 2026Anovo Specialty Pharmacy serves as the exclusive distribution partner for HEMANGEOL and other Eton products. The partnership includes integration with Eton Cares patient support program offering $0 co-pay for eligible commercially insured patients.
• Pierre Fabre Medicament SascoreChannel Partner/ Reseller/ Distributor · 2 March 2026Eton in-licensed U.S. commercialization rights to HEMANGEOL (propranolol hydrochloride) Oral Solution from Pierre Fabre. HEMANGEOL is the only FDA-approved treatment for proliferating infantile hemangioma requiring systemic therapy. Eton took over U.S. commercialization on May 1, 2026. Transaction expected to be accretive to 2026 earnings.
• CROSSJECTminorStrategic or Co-development Partner · 1 March 2025In March 2025, CROSSJECT partnered with Eton Pharmaceuticals to develop and commercialize ET-801, a ready-to-use hydrocortisone formulation for treating adrenal insufficiency crises. The partnership leverages Eton's U.S. hospital market expertise for this adrenal insufficiency treatment.
• IpsencoreStrategic or Co-development Partner · 3 October 2024Eton Pharmaceuticals announced agreement to acquire Increlex (mecasermin) from Ipsen, expected to complete near the end of 2024. The acquisition strengthens Eton's portfolio for treating ultra-rare pediatric conditions, with immediate US commercialization and a transition period for global supply. Increlex is approved in 40 territories and treats severe IGF-1 deficiency.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Ultragenyx Pharmaceutical: Commercial-stage rare disease biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic diseases. Comparable in targeting small patient populations with specialty-distributed therapeutics.
• ANI Pharmaceuticals: U.S. specialty pharmaceutical company that acquires, develops, and commercializes branded and generic prescription pharmaceuticals, including rare disease products. Similar in-licensing and acquisition-driven growth model.
• Amneal Pharmaceuticals: Specialty and generics pharmaceutical company with rare disease and specialty distribution capabilities. Comparable in building a portfolio through acquisitions and licensing of niche, difficult-to-formulate products.
• PTC Therapeutics: Commercial-stage biopharmaceutical company focused on rare disorders, particularly those with CNS and metabolic components. Comparable in targeting small rare disease populations with specialty-distributed therapies.
• Scilex Holding (Scilex Pharmaceuticals): Specialty pharmaceutical company focused on non-opioid pain and rare/specialty products, with similar small-cap commercialization profile and reliance on specialty distribution channels.

Broad incumbents

• BioMarin Pharmaceutical: Established rare disease-focused biopharmaceutical company with multiple commercial products for ultra-rare conditions. Larger and more diversified than Eton but operates the same orphan-disease commercialization model.
• Jazz Pharmaceuticals: Specialty pharmaceutical company with significant rare disease and neurology exposure. Comparable in distributing specialty medicines for limited patient populations, though at a much larger scale.
• Recordati Rare Diseases: European-headquartered specialty and rare disease pharmaceutical group with a dedicated rare disease business unit. Comparable model of acquiring and commercializing treatments for rare conditions globally.
• Mallinckrodt Pharmaceuticals: Specialty pharmaceutical company historically focused on rare diseases, branded specialty products, and hospital therapeutics. Comparable in commercializing niche, often small-population therapies.

Regional players

• Hikma Pharmaceuticals: Specialty pharmaceutical company with branded and rare disease product lines across the Middle East, Europe, and the U.S. Comparable in product-acquisition-led specialty pharma growth, though with broader geographic footprint.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/61569281801722
• LinkedInlinkedin.com/company/etonpharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds4 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eton Pharmaceuticals